Patents by Inventor Caroline Breitbach

Caroline Breitbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
    Patent number: 10434169
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 8, 2019
    Assignees: SILLAJEN, INC, SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
    Publication number: 20180214538
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 2, 2018
    Applicants: SILLAJEN BIOTHERAPEUTICS, INC., SILLAJEN, INC.
    Inventors: David KIRN, John BELL, Caroline BREITBACH, Anne MOON, Tae-Ho HWANG, Yu Kyoung LEE, Mi-kyung KIM
  • Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
    Patent number: 9919047
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 20, 2018
    Assignees: SILLAJEN, INC., SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • Oncolytic vaccinia virus combination cancer therapy
    Patent number: 9180151
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: November 10, 2015
    Assignee: SillaJen Biotherapeutics, Inc.
    Inventors: David Kirn, Caroline Breitbach
  • Oncolytic Vaccinia Virus Combination Cancer Therapy
    Publication number: 20140322173
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Application
    Filed: May 8, 2014
    Publication date: October 30, 2014
    Applicant: JENNEREX, INC.
    Inventors: DAVID KIRN, CAROLINE BREITBACH
  • Oncolytic vaccinia virus combination cancer therapy
    Patent number: 8747837
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: June 10, 2014
    Assignee: Jennerex, Inc.
    Inventors: David Kirn, Caroline Breitbach
  • ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY
    Publication number: 20120230958
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Application
    Filed: September 14, 2010
    Publication date: September 13, 2012
    Applicant: JENNEREX, INC.
    Inventors: David Kirn, Caroline Breitbach